Where no man has gone before: the technologies being used to explore MM epigenetic factors

In recent years, researchers have become increasingly aware of the fact that epigenetic alterations can contribute to the formation of multiple myeloma (MM); however, our understanding of these remain... Author: VJHemOnc Added: 12/06/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Source Type: news
Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Drug: Ixazomib Citrate;   Drug: Pevonedistat Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
One of my Italian blog readers sent me this link today: http://goo.gl/AEwRXo I realize the article is in Italian, but hey, you’re in luck : you can read the full study, on which the Italian article is based, in English…at this link: http://goo.gl/9U8NoN In any case, I’m going to give you a brief summary (based only on the article. I need more time to read/go through the full study). Here goes. Researchers at the Ospedale di San Raffaele in Milan have discovered that a particular type of gut bacteria, called Prevotella heparinolytica, plays a big role in the proliferation of some of the inf...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll Arianna Brevi gut bacteria myeloma Prevotella heparinolytica Source Type: blogs
Publication date: March 2019Source: International Journal of Paleopathology, Volume 24Author(s): Giulia Riccomi, Gino Fornaciari, Valentina GiuffraAbstractThis paper provides a critical literature review concerning paleopathological evidence of multiple myeloma discovered both in the Old and in the New World. A critical assessment of the bioarchaeological and paleopathological documentary sources permitted to identify a total of 25 ascertained cases of multiple myeloma from different geographical areas in the world ranging from Prehistoric times up to the Contemporary age. The distribution of multiple myeloma findings in p...
Source: International Journal of Paleopathology - Category: Pathology Source Type: research
Multiple myeloma (MM) is a malignant disorder of plasma cells primarily affecting elderly patients with a median age at diagnosis in the late 60s to early 70s [1]. It is the second most commonly diagnosed hematological neoplasm with an estimated incidence of 30,280 cases in 2017 and prevalence of 118,539 in 2014 [2]. With effective new agents now available including proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies, significant advances have been made in the treatment of MM.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Authors: Giralt S, Seifter E Abstract With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018. PMID: 30504298 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Authors: Usmani SZ, Seifter E PMID: 30504297 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Authors: Wildes TM, Anderson KC Abstract Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated ...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Authors: Facon T, Anderson K Abstract Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated tot...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Condition:   Multiple Myeloma Intervention:   Drug: Daratumumab Sponsor:   Johnson & Johnson Private Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Myeloma